Bone Data


DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Significantly less impact on BMD1,2

Mean % change in lumbar spine and hip BMD at Week 48

The long-term clinical significance of changes in BMD is not known.1

  • At Week 48, BMD declines of ≥5% at the lumbar spine and ≥7% at the total hip were experienced by 4% and 1% of patients, respectively, in both treatment arms1
  • Analysis of these parameters was conducted in a subset of the study population (n=383)1,2
  • BMD was assessed at baseline and at Week 48 by dual-energy X-ray absorptiometry (DXA) scans1
  • DESCOVY FOR PrEP had less impact on BMD compared with TRUVADA.1 Increases in BMD observed in DISCOVER patients may be consistent with innate bone development

Many of the patients in the DISCOVER Trial were under 30, an age at which many people still experience bone growth.2-4

DESCOVY Co-pay Support

BMD=bone mineral density.